PH12022553396A1 - Sulcardine administration for treatment of acute atrial fibrillation - Google Patents

Sulcardine administration for treatment of acute atrial fibrillation

Info

Publication number
PH12022553396A1
PH12022553396A1 PH1/2022/553396A PH12022553396A PH12022553396A1 PH 12022553396 A1 PH12022553396 A1 PH 12022553396A1 PH 12022553396 A PH12022553396 A PH 12022553396A PH 12022553396 A1 PH12022553396 A1 PH 12022553396A1
Authority
PH
Philippines
Prior art keywords
sulcardine
administration
treatment
atrial fibrillation
acute atrial
Prior art date
Application number
PH1/2022/553396A
Other languages
English (en)
Inventor
Gary Elliott
Mireille Gillings
Robert Goodenow
Jay Mason
Waldemar Radziszewski
Suzanne Romano
Original Assignee
Huyabio Int Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huyabio Int Llc filed Critical Huyabio Int Llc
Publication of PH12022553396A1 publication Critical patent/PH12022553396A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PH1/2022/553396A 2020-06-12 2021-06-11 Sulcardine administration for treatment of acute atrial fibrillation PH12022553396A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063038664P 2020-06-12 2020-06-12
PCT/US2021/037098 WO2021252959A1 (en) 2020-06-12 2021-06-11 Sulcardine administration for treatment of acute atrial fibrillation

Publications (1)

Publication Number Publication Date
PH12022553396A1 true PH12022553396A1 (en) 2024-04-22

Family

ID=78824214

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/553396A PH12022553396A1 (en) 2020-06-12 2021-06-11 Sulcardine administration for treatment of acute atrial fibrillation

Country Status (14)

Country Link
US (2) US11813245B2 (cg-RX-API-DMAC10.html)
EP (1) EP4164633A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023529196A (cg-RX-API-DMAC10.html)
KR (1) KR20230024347A (cg-RX-API-DMAC10.html)
CN (1) CN116723836A (cg-RX-API-DMAC10.html)
AU (1) AU2021288056A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022025216A2 (cg-RX-API-DMAC10.html)
CA (1) CA3182015A1 (cg-RX-API-DMAC10.html)
CL (1) CL2022003501A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023000194A2 (cg-RX-API-DMAC10.html)
IL (1) IL298907A (cg-RX-API-DMAC10.html)
MX (1) MX2022015834A (cg-RX-API-DMAC10.html)
PH (1) PH12022553396A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021252959A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11813245B2 (en) * 2020-06-12 2023-11-14 Huyabio International, Llc Sulcardine administration for treatment of acute atrial fibrillation
WO2026036095A1 (en) * 2024-08-08 2026-02-12 Huyabio International, Llc J-Tp PROTECTION

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1172908C (zh) * 1999-12-10 2004-10-27 中国科学院上海药物研究所 N-取代苄基或苯基芳香磺酰胺化合物及其用途
CN1939298A (zh) 2005-09-29 2007-04-04 中国科学院上海药物研究所 硫酸舒欣啶固体和靶向制剂及其制备方法
US8541464B2 (en) * 2009-11-17 2013-09-24 HUYA Biosciences International LLC Treatment of atrial fibrillation
WO2011062903A2 (en) * 2009-11-17 2011-05-26 Elliott Gary T Slow infusion of sulcardine and its salts
EP3302442B1 (en) 2015-06-03 2024-10-16 Triastek, Inc. Dosage forms and use thereof
AU2017261372B2 (en) 2016-05-05 2019-02-14 Triastek, Inc. Controlled release dosage form
AU2018212273B2 (en) 2017-01-26 2023-12-21 Triastek, Inc. Dosage forms of controlled release at specific gastrointestinal sites
WO2020123824A1 (en) * 2018-12-13 2020-06-18 Huya Bioscience International, Llc Sulcardine administration for treatment of acute atrial fibrillation
KR102405199B1 (ko) * 2019-01-29 2022-06-02 후야 바이오사이언스 인터내셔널 엘엘씨 설카딘 염
US11813245B2 (en) * 2020-06-12 2023-11-14 Huyabio International, Llc Sulcardine administration for treatment of acute atrial fibrillation

Also Published As

Publication number Publication date
US11813245B2 (en) 2023-11-14
US20240058304A1 (en) 2024-02-22
IL298907A (en) 2023-02-01
EP4164633A4 (en) 2024-07-31
WO2021252959A1 (en) 2021-12-16
JP2023529196A (ja) 2023-07-07
CL2022003501A1 (es) 2023-06-09
KR20230024347A (ko) 2023-02-20
BR112022025216A2 (pt) 2023-04-04
EP4164633A1 (en) 2023-04-19
US12465587B2 (en) 2025-11-11
CN116723836A (zh) 2023-09-08
US20210386708A1 (en) 2021-12-16
AU2021288056A1 (en) 2023-02-09
CO2023000194A2 (es) 2023-03-27
CA3182015A1 (en) 2021-12-16
MX2022015834A (es) 2023-04-04

Similar Documents

Publication Publication Date Title
ZA202104166B (en) Sulcardine administration for treatment of acute atrial fibrillation
MX2022004259A (es) Inhibidores de mek para el tratamiento de infecciones por hantavirus.
PH12020551427A1 (en) Epinephrine spray formulations
MX2022004051A (es) Composicion novedosa para el cuidado de la piel.
MX2025000166A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo
BR112021020247A2 (pt) Composições e métodos para melhorar a saúde da pele e para o tratamento e prevenção de doenças, distúrbios e afecções associadas a micróbios patogênicos
EP4684836A3 (en) Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
MX387885B (es) Inhibidores de ezh2 para tratar linfomas.
MX2018001842A (es) Composiciones que incluyen extractos de ampelopsis grossedentata y albizia julibrissin y métodos para uso.
AR079552A1 (es) Metodo para el tratamiento de la fibrilacion atrial. formulacion farmaceutica
ZA202300259B (en) Compound for the treatment of coronaviral infections
MX2022015834A (es) Administracion de sulcardina para el tratamiento de fibrilacion auricular aguda.
MX2020012018A (es) Composiciones para el tratamiento de condiciones de la piel.
BR112022015768A2 (pt) Métodos de tratamento e prevenção de arritmias de enxerto
MX2022004054A (es) Composicion novedosa para el cuidado de la piel.
MX2022004052A (es) Composicion novedosa para el cuidado de la piel.
MX2017015012A (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
CL2022003039A1 (es) Inhibidores de il4i1 y métodos de uso.
PE20200600A1 (es) Composiciones y metodos para promover el crecimiento del cabello con inhibidores de mpc
MX2025001990A (es) Agente terapeutico y metodo terapeutico que son para pacientes con cancer que presentan deterioro funcional de la proteina del retinoblastoma (rb1) y que implican el uso concomitante de inhibidor del factor de transcripcion 1 de mielina (myt1) y agente quimioterapeutico
MX2024014121A (es) Metodos y composiciones para el tratamiento del exceso de glucocorticoides
EP4591928A3 (en) Composition for the treatment of gastroesophageal reflux comprising hyaluronic acid
MX2022004050A (es) Composicion novedosa para el cuidado de la piel.
MX363200B (es) Composición odontológica de papaína en gel para el tratamiento atraumático de caries y método para prepararla.
WO2021242844A8 (en) Grk2 inhibitors and uses thereof